Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Jupiter Neurosciences, Inc. Common Stock (JUNS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: JUNS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 200.22M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 136606 | Beta - | 52 Weeks Range 0.55 - 19.51 | Updated Date 03/8/2025 |
52 Weeks Range 0.55 - 19.51 | Updated Date 03/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 202546214 | Price to Sales(TTM) - |
Enterprise Value 202546214 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating 5 | Target Price - | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Jupiter Neurosciences, Inc. Common Stock
Company Overview
History and Background
Jupiter Neurosciences, Inc. is a pharmaceutical company focused on the development of therapies for neurological diseases. Founded in 2015, the company has focused on its lead candidate, JOTROL, which is being developed to address unmet needs in neurodegenerative disorders.
Core Business Areas
- Drug Development: Researching, developing, and commercializing therapies for neurodegenerative diseases, including Mucopolysaccharidoses (MPS) and Mild to Moderate Alzheimers disease.
Leadership and Structure
Dr. Chua, CEO leads the company. The organizational structure includes research and development, clinical operations, and regulatory affairs departments.
Top Products and Market Share
Key Offerings
- JOTROL: JOTROL is an oral therapy being developed for the treatment of MPS (Mucopolysaccharidoses) and Mild to Moderate Alzheimers. It is undergoing clinical trials. Data on market share and revenue is not yet available as the product is still in development. Potential competitors will depend on the indications achieved and successful commercialization.
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurodegenerative diseases is growing due to an aging population and increasing awareness of these conditions. There is a high unmet need for effective treatments.
Positioning
Jupiter Neurosciences is positioned as a company focused on developing innovative therapies for unmet medical needs in neurodegenerative diseases. Their competitive advantage lies in their novel approach and intellectual property.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease therapies is estimated to be in the billions of dollars, with a significant portion attributed to conditions like Alzheimer's disease and MPS. Jupiter Neurosciences is positioned to capture a share of this market if JOTROL proves effective and receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced management team
- Intellectual property protection
Weaknesses
- Limited financial resources
- Single product pipeline
- Clinical trial risks
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory fast track designations
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- SNY
- BMY
- LLY
Competitive Landscape
Jupiter Neurosciences faces significant competition from established pharmaceutical companies. Their success depends on demonstrating the superior efficacy and safety of JOTROL.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on clinical trial progress and regulatory approvals.
Future Projections: Future growth projections depend on the success of JOTROL in clinical trials and regulatory approval. Analyst estimates are speculative at this stage.
Recent Initiatives: Recent initiatives include advancing JOTROL through clinical trials and seeking regulatory designations.
Summary
Jupiter Neurosciences is a development-stage company with a promising lead candidate, JOTROL, targeting neurodegenerative diseases. However, the company faces significant risks related to clinical trial outcomes and regulatory approval. They require additional funding to operate and compete with well established players. While JOTROL represents a significant opportunity if successful, it also poses a risk given the focus of the whole company on it.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
SNY
Sanofi ADR
SNY
Sanofi ADR
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jupiter Neurosciences, Inc. Common Stock
Exchange NASDAQ | Headquaters Jupiter, FL, United States | ||
IPO Launch date 2024-12-03 | Co-Founder, CEO & Chairman of the Board Mr. Christer Rosen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://jupiterneurosciences.com |
Full time employees 4 | Website https://jupiterneurosciences.com | ||
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. The company is also developing JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, it is developing JNS115, which is in Phase II trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to Advance Phase 2a Parkinson's Trial. The company has a strategic partnership with Aquanova AG to jointly develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2015 and is headquartered in Jupiter, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.